Research Spotlight

Posted April 16th 2020

Designing health care: A community health science solution for reducing health disparities by integrating social determinants and the effects of place.

Heather Kitzman Ph.D.

Heather Kitzman Ph.D.

DeHaven, M. J., N. A. Gimpel, D. Gutierrez, H. Kitzman-Carmichael and K. Revens (2020). “Designing health care: A community health science solution for reducing health disparities by integrating social determinants and the effects of place.” J Eval Clin Pract Mar 10. [Epub ahead of print].

Full text of this article.

BACKGROUND: In the United States chronic illnesses have become a way of life for multiple generations – they are the number one cause of death and disability (accounting for more than 70% of deaths), 60% of American adults have at least one chronic disease, and 40% have multiple chronic conditions. Although multiple factors contribute to the growth in chronic disease prevalence, a major factor has been overreliance on health care systems for promoting health and preventing disease. Large health care systems are ill equipped for this role since they are designed to detect, treat, and manage disease, not to promote health or address the underlying causes of disease. METHODS: Improving health outcomes in the U.S. will require implementing broad-based prevention strategies combining biological, behavioral, and societal variables that move beyond clinical care. According to community medicine, clinical care alone cannot create, support, or maintain health. Rather, health can only ensue from combining clinical care with epidemiology and community organization, because health is a social outcome resulting from a combination of clinical science, collective responsibility, and informed social action. RESULTS: During the past 20 years, our team has developed an operational community medicine approach known as community health science. Our model provides a simple framework for integrating clinical care, population health, and community organization, using community-based participatory research (CBPR) practices for developing place-based initiatives. In the present paper, we present a brief overview of the model and describe its evolution, applications, and outcomes in two major urban environments. CONCLUSION: The paper demonstrates means for integrating the social determinants of health into collaborative place-based approaches, for aligning community assets and reducing health disparities. It concludes by discussing how asset-based community development can promote social connectivity and improve health, and how our approach reflects the emerging national consensus on the importance of place-based population system change.


Posted April 16th 2020

Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.

Milton Packer M.D.

Milton Packer M.D.

Cunningham, J. W., M. Vaduganathan, B. L. Claggett, M. R. Zile, I. S. Anand, M. Packer, F. Zannad, C. S. P. Lam, S. Janssens, P. S. Jhund, L. Kober, J. Rouleau, S. J. Shah, V. K. Chopra, V. C. Shi, M. P. Lefkowitz, M. F. Prescott, M. A. Pfeffer, J. J. V. McMurray and S. D. Solomon (2020). “Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.” JACC Heart Fail Mar 26. pii: S2213-1779(20)30146-3. [Epub ahead of print].

Full text of this article.

OBJECTIVES: The authors sought to evaluate the prognostic significance of baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP), whether NT-proBNP modified the treatment response to sacubitril/valsartan, and the treatment effect of sacubitril/valsartan on NT-proBNP overall and in key subgroups. BACKGROUND: Sacubitril/valsartan reduces NT-proBNP in heart failure (HF) with both reduced and preserved ejection fraction (EF), but did not significantly reduce total HF hospitalizations and cardiovascular death compared with valsartan in patients with HF with preserved EF (HFpEF). METHODS: In the PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) trial, 4,796 patients with HFpEF and elevated NT-proBNP were randomized to sacubitril/valsartan or valsartan. NT-proBNP was measured at screening in all patients and at 5 subsequent times in >2,700 patients: before, between, and after sequential valsartan and sacubitril/valsartan run-in periods, and 16 and 48 weeks post-randomization. RESULTS: Median NT-proBNP was 911 pg/ml (interquartile range: 464 to 1,613 pg/ml) at screening. Screening NT-proBNP was strongly associated with the primary endpoint, total HF hospitalizations and cardiovascular death (rate ratio [RR]: 1.68 per log increase in NT-proBNP, 95% confidence interval [CI]: 1.53 to 1.85; p < 0.001). This relationship was stronger in patients with atrial fibrillation (adjusted RR: 2.33 [95% CI: 1.89 to 2.87] vs. 1.58 [95% CI: 1.42 to 1.75] in patients without atrial fibrillation; p interaction <0.001) and weaker in obese patients (adjusted RR: 1.50 [95% CI: 1.31 to 1.71] vs. 1.92 [95% CI: 1.70 to 2.17] in nonobese patients; p interaction <0.001). Screening NT-proBNP did not modify the treatment effect of sacubitril/valsartan compared with valsartan (p interaction = 0.96). Sacubitril/valsartan reduced NT-proBNP by 19% (95% CI: 14% to 23%; p < 0.001) compared with valsartan 16 weeks post-randomization, with similar reductions in men (20%) and women (18%), and in patients with left ventricular EF 57% (18%). Decreases in NT-proBNP predicted lower subsequent risk of the primary endpoint. CONCLUSIONS: Baseline NT-proBNP predicted HF events but did not modify the sacubitril/valsartan treatment effect in patients with HFpEF. Sacubitril/valsartan reduced NT-proBNP consistently in men and women, and in patients with lower or higher EF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).


Posted April 16th 2020

Preoperative Dobutamine Stress Echocardiography and Clinical Factors for Assessment of Cardiac Risk after Noncardiac Surgery.

R. Jay Widmer, M.D.

R. Jay Widmer, M.D.

Cullen, M. W., R. B. McCully, R. J. Widmer, D. R. Schroeder, B. R. Salonen, D. Raslau, K. K. Sundsted, A. B. Mohabbat, B. M. Dougan, D. M. Bierle, A. Widmer, D. Banerjee, P. Gaba, R. Tellez, G. C. Kane, P. A. Pellikka and K. F. Mauck (2020). “Preoperative Dobutamine Stress Echocardiography and Clinical Factors for Assessment of Cardiac Risk after Noncardiac Surgery.” J Am Soc Echocardiogr 33(4): 423-432.

Full text of this article.

BACKGROUND: The role of dobutamine stress echocardiography (DSE) in the risk stratification of patients undergoing noncardiac surgery in the current era is unclear. The aim of this study was to evaluate the yield of DSE and the additive role of DSE to clinical criteria for preoperative risk stratification of patients undergoing noncardiac surgery. METHODS: The study included 4,494 patients undergoing DSE /=3 had an event rate of 7.5%. The event rates for patients with wall motion score index >/=1.7 at baseline, left ventricular ejection fractions <40% at peak stress, or ischemic thresholds <70% of age-predicted maximal heart rate were 7.1%, 8.6%, and 7.9%, respectively. After adjusting for clinical variables, the overall result of DSE (P < .001), baseline and peak-stress wall motion score index (P < .001 and P = .014, respectively), peak-stress left ventricular ejection fraction (P < .001), and the number of ischemic segments (P = .027) were all associated with postoperative cardiac events. Incremental multivariate analysis demonstrated that an overall abnormal result on DSE, added to clinical variables, was associated with an increased risk for postoperative cardiac events (odds ratio, 2.07; 95% CI, 1.35-3.17; P < .001). CONCLUSIONS: Baseline and peak-stress findings on preoperative DSE add to the prognostic utility of clinical variables for stratifying cardiac risk after noncardiac surgery.


Posted April 16th 2020

Not All Episodes of Acute Kidney Injury Are Equal in Patients With Cirrhosis, Based on Patterns of Renal Dysfunction.

Sumeet K. Asrani M.D.

Sumeet K. Asrani M.D.

Cullaro, G. and S. K. Asrani (2020). “Not All Episodes of Acute Kidney Injury Are Equal in Patients With Cirrhosis, Based on Patterns of Renal Dysfunction.” Clin Gastroenterol Hepatol Mar 14. pii: S1542-3565(20)30332-3. [Epub ahead of print].

Full text of this article.

Renal dysfunction is a major driver of mortality in patients with cirrhosis—2 in every 3 patients will have significant kidney dysfunction at the time of their death.1 Although surrogates of kidney dysfunction—serum creatinine, serum sodium—are included in the
Model for End Stage Liver Disease (MELD) and MELDSodium scores, they do little to account for the patterns or pathology of injury that drive kidney dysfunction among patients with cirrhosis. This is a major limitation, as kidney dysfunction phenotypes have varying impact on mortality. Therefore, there is an ever increasing clinical need to better understand the intricacies and implications of kidney function patterns among patients
with cirrhosis. [Excerpt from Editorial]


Posted April 16th 2020

Gastroschisis prevalence substantially decreased from 2009 through 2018 after a 3-fold increase from 1997 to 2008.

Veeral N. Tolia M.D.

Veeral N. Tolia M.D.

Clark, R. H., J. Sousa, M. M. Laughon and V. N. Tolia (2020). “Gastroschisis prevalence substantially decreased from 2009 through 2018 after a 3-fold increase from 1997 to 2008.” J Pediatr Surg Mar 24. pii: S0022-3468(20)30206-2. [Epub ahead of print].

Full text of this article.

BACKGROUND/PURPOSE: Gastroschisis incidence increased 300% in the United States from 1998 to 2013. We sought to assess trends in gastroschisis prevalence in the United States from 1997 to 2018 from a large NICU dataset. METHODS: We performed a retrospective review of all infants in the Pediatrix Clinical Data Warehouse from 1997 to 2018. Prevalence was calculated as number of infants with gastroschisis (among all NICU admissions) divided by the total number of NICU infants. Trends were analyzed by year and also after stratification of the cohort by maternal age. RESULTS: We included 1,433,027 infants discharged over the study period. Between 1997 and 2008, the prevalence of gastroschisis increased from 2.9 to 6.4 per 1000 infants (p<0.01) and then decreased to 3.3 per 1000 infants (p<0.01) by 2018. Younger mothers (<20years old) had the highest rate of gastroschisis and the largest recent decrease in prevalence of gastroschisis (20.8/1000 infant in 2008 to 13.1/1000 infants in 2018, p<0.01). Prevalence of gastroschisis decreased within each maternal age group. CONCLUSION: The prevalence of gastroschisis increased from 1997 to 2008 then decreased from 2009 to 2018 and is now similar to that reported in 1997. Future research that identifies changes in underlying risk factors may help elucidate the pathogenesis of this disease. LEVEL OF EVIDENCE: Level II prognosis study.